Keymed Biosciences, Inc. (2162) Stock Statistics & Valuation Metrics

Keymed Biosciences, Inc. has a market cap or net worth of HK$22.84B. The enterprise value is HK$14.44B.

Keymed Biosciences, Inc. has 298,735,570 shares outstanding. The number of shares has decreased by -2.65% in one year.

Keymed Biosciences, Inc.’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -14.99%.

The current PE Ratio of Keymed Biosciences, Inc. is ―. Keymed Biosciences, Inc.’s PEG ratio is 4.63.

In the last 12 months, Keymed Biosciences, Inc. had revenue of 697.77M and earned -509.11M in profits. Earnings per share was -1.86.

In the last 12 months, operating cash flow was -549.88M and capital expenditures -333.61M, giving a free cash flow of -883.50M billion.

Keymed Biosciences, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Keymed Biosciences, Inc. upcoming earnings date is Sep 1, 2026, TBA (Confirmed).

Keymed Biosciences, Inc. as a current ratio of 2.90, with Debt / Equity ratio of 28.42%

In the past 12 months, Keymed Biosciences, Inc. has paid 1.83M in taxes.

Keymed Biosciences, Inc. EV to EBITDA ratio is -27.38, with an EV/FCF ratio of -12.77.

Keymed Biosciences, Inc. has HK$1.96B in cash and marketable securities with HK$788.88M in debt, giving a net cash position of HK$1.18B billion.

Gross margin is 80.99%, with operating margin of -83.82%, and net profit margin of -72.96%.

The average price target for Keymed Biosciences, Inc. is HK$93.24, which is 11.43% higher than the current price. The consensus rating is Moderate Buy